Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Treasury Shares: 2017-2020

Historic Treasury Shares for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2020 value amounting to $26,923.

  • Summit Therapeutics' Treasury Shares was N/A to $26,923 in Q4 2020 from the same period last year, while for Dec 2020 it was $26,923, marking a year-over-year change of. This contributed to the annual value of $26,923 for FY2020, which is N/A change from last year.
  • As of Q4 2020, Summit Therapeutics' Treasury Shares stood at $26,923, which was down 99.89% from $25.3 million recorded in Q1 2020.
  • Summit Therapeutics' 5-year Treasury Shares high stood at $26.6 million for Q1 2019, and its period low was $0.36 during Q4 2019.
  • Over the past 3 years, Summit Therapeutics' median Treasury Shares value was $2.23 (recorded in 2018), while the average stood at $6.5 million.
  • As far as peak fluctuations go, Summit Therapeutics' Treasury Shares soared by 42.37% in 2018, and later plummeted by 83.28% in 2019.
  • Quarterly analysis of 4 years shows Summit Therapeutics' Treasury Shares stood at $1.88 in 2017, then tumbled by 71.69% to $0.53 in 2018, then slumped by 32.58% to $0.36 in 2019, then dropped by 4.84% to $26,923 in 2020.
  • Its Treasury Shares stands at $26,923 for Q4 2020, versus $25.3 million for Q1 2020 and $0.36 for Q4 2019.